Lv1
30 积分 2024-08-28 加入
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
14小时前
待确认
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages
15小时前
已完结
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
3个月前
已完结
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
4个月前
已完结
Immunology and immunotherapy of cholangiocarcinoma
4个月前
已完结
皖公网安备34019202002308
